用超声波驱动的抗癌药物的联合组装成无载体粒子
Mirudula Mohankumar1, Soraia Fernandes1,2, Francesca Cavalieri2,3
1Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.
ACS nano
|March 26, 2025
概括
这项研究引入了无载体纳米药物 (NDs),使用超声波结合抗癌药物,克服耐药性. 这些纳米药物显示出对小鼠抗药性癌细胞和瘤的增强疗效.
科学领域:
- 在瘤学瘤学.
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
背景情况:
- 癌症的耐药性需要新的治疗策略.
- 使用纳米粒子载体的组合疗法提供了协同效应,但可能会引起安全问题.
- 无载体系统可以减轻物质诱导的毒性,同时保持治疗效益.
研究的目的:
- 开发超声驱动的无载体纳米药物 (NDs),用于增强抗癌联合治疗.
- 研究联合组装的纳米药物对抗耐药癌细胞和瘤的疗效.
- 评估这些新型纳米药物系统的安全性和治疗潜力.
主要方法:
- 协同作用的抗癌药物 (Venetoclax与Doxorubicin或S63845) 的超声驱动自组装成无载体纳米粒子.
- 在维内托克拉克斯抗性SKOV-3细胞中抗癌活性的体外评估.
- 使用SKOV-3异种移植小鼠模型和瘤组织分析的体内疗效研究.
主要成果:
- 同组装的纳米药物 (NDs) 在体外显示出与自由药物和单组件NDs相比显著更高的抗癌活性.
- 与免费的Venetoclax相比,含有Venetoclax和Doxorubicin的纳米药物在小鼠中延长了6天以上的存活时间.
- 显微镜证实了纳米药物诱导的较大的瘤组织损伤和亡.
结论:
- 超声组装的无载体纳米药物代表了克服癌症药物耐药性的有希望的平台.
- 这种方法结合了高表面积,缓慢释放和协同药物作用的好处.
- 声波驱动的无载体系统为抗癌联合治疗提供了更安全,更有效的替代方案.
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165